AdRTSIL-12 is under clinical development by Alaunos Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AdRTSIL-12’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 13 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 13 Nov 2021 increased AdRTSIL-12’s LoA and PTSR for Recurrent Glioblastoma Multiforme (GBM).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AdRTSIL-12 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AdRTSIL-12 overview

Ad-RTS-IL-12 (INXN 2001) is under development for the treatment high-grade glioma, newly diagnosed recurrent or progressive glioblastoma, grade III malignant gliomas. The drug candidate is administered by intratumoral route. It is an adenovirus vector engineered to express hIL-12. Production of IL-12 within cells is tightly regulated by the RheoSwitch Therapeutic System (RTS), a gene switch controlled by an orally administered activator ligand (AL), veledimex (INXN-1001). It was also under development for metastatic melanoma, metastatic breast cancer, anaplastic astrocytoma, and colon cancer.

It was under development for the treatment of pediatric diffuse intrinsic pontine glioma.

Alaunos Therapeutics overview

Alaunos Therapeutics formerly ZIOPHARM Oncology, is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune response. The company also provides Sleeping Beauty, a clinically-advanced non-viral cell therapy technology which helps in the manufacturing of genetically modified chimeric antigen receptors (CARs) and T-cell receptors (TCRs) targeting specific tumor-derived antigens. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. The company is headquartered in Boston, Massachusetts, the US.

Quick View AdRTSIL-12 LOA Data

Report Segments
  • Innovator
Drug Name
  • AdRTSIL-12
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
  • Undisclosed
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.